Esophageal Stents (including Benign Indication)
Boston Scientific stent technology is built on science and innovation to expand options available for patient treatment and management.
Building on the best of Boston Scientific’s industryleading stents, the WallFlex Stent seeks to deliver luminal patency through a combination of flexibility and control to support your goal of optimized patient care.
The WallFlex Esophageal Stent is available in fully and partially covered options and avariety of lengths and widths.
WallFlex Esophageal Stent Details
The Progressive Step Flared Ends may assist in anchoring the stent within the esophageal lumen.
The multiple wire braided construction is engineered to allow the WallFlex Esophageal Stent to adjust to forces from the esophageal anatomy such as strictures and peristalsis. The design allows for gradual stent expansion, which is typically complete after 24-72hrs.
Tissue InGrowth Prevention
The Permalume™ Silicone Covering extends the entire length of the WallFlex Esophageal Stent in the fully covered version and is designed to prevent tumor ingrowth as well as seal concurrent esophageal fistulas and help reduce food impaction.
The Teflon™ Coated Polyester Removal Suture facilitates removal during the initial stent placement procedure.
The Nitinol construction allows for clear visualization during fluoroscopy, ensuring accurate stent placement.
Delivery System Details
The 18.5 French (6.17mm), low profile delivery system is designed to traverse tight strictures.*
The Endoscopic Transition Zone is designed to aid in stent placement accuracy when deployed using endoscopic visualization.
Stent Placement Accuracy
The coaxial delivery system is designed to result in 1:1 stent deployment.
The fully covered stent may be reconstrained up to 75% of deployment and 2 times during the initial stent placement procedure.**
* Predilation may not be required, depending on stricture lumen diameter.
** A stent can not be reconstrained after the reconstrainment limit has been exceeded.
WallFlex™ Esophageal Stents
Building on the best of Boston Scientific’s industry-leading stents, the WallFlex™ Stent seeks to deliver luminal patency through a combination of flexibility and control to support your goal of optimized patient care. The stent is available in fully and partially covered options and a variety of lengths and widths.
|Order Number||Stent O.D. (mm)||Proximal / Distal Flares O.D. (mm)||Stent Length (cm)||Catheter Diameter (Fr / mm)||System Length (cm)|
|M00516700||18||25 / 23||10.3||18.5 / 6.17||78|
|M00516710||18||25 / 23||12.3||18.5 / 6.17||78|
|M00516720||18||25 / 23||15.3||18.5 / 6.17||78|
|M00516730||23||28 / 28||10.5||18.5 / 6.17||78|
|M00516740||23||28 / 28||12.5||18.5 / 6.17||78|
|M00516750||23||28 / 28||15.5||18.5 / 6.17||78|
|Order Number||Stent O.D. (mm)||Proximal / Distal Flares O.D. (mm)||Stent Length (cm)||Covered Length (cm)||Catheter Diameter (Fr / mm)||System Length (cm)|
|M00516900||18||23 / 23||10||7||18.5 / 6.17||120|
|M00516910||18||23 / 23||12||9||18.5 / 6.17||120|
|M00516920||18||23 / 23||15||12||18.5 / 6.17||120|
*Recommended Guidewire .038" Jagwire™ Guidewire, Order #5662, (see below).
1 Product with this symbol may be used in Magnetic Resonance environment according to the conditions described in Directions for Use.
New study results found that placement of a WallFlex Fully Covered Esophageal Stent resulted in safe and effective palliation of malignant dysphagia
Dr. Allesandro Repici et al. authored the largest study on the WallFlex Fully Covered Esophageal Stent, which was published in the December 2014 issue of Digestive and Liver Disease Journal. The goal of the study was to assess the clinical (recurrent dysphagia) and technical success using the WallFlex Fully Covered Esophageal Stent in patients with dysphagia due to primary inoperable esophageal cancer.
The study found that placement of a WallFlex Fully Covered Esophageal Stent resulted in safe and effective palliation of malignant dysphagia. The median dysphagia scores improved from “3” (ability to swallow liquids only) to “1” (ability to eat some solid food) at both fourteen days and four weeks after stent placement. In addition, twentyfour of the eightytwo patients (29.2%) went on to receive chemo and/or radiotherapy after stent placement.
The article, Management of Inoperable Malignant Oesophageal Strictures with Fully Covered WallFlex Stent: A multicentre Prospective Study is available at https://www.ncbi.nlm.nih.gov/pubmed/25262010.
Presented by Rafael S. Andrade, M.D., Minneapolis, Minnesota (USA)
Presented by Rafael S. Andrade, M.D. and Jonathan D’Cunha, M.D., Minneapolis, Minnesota (USA)
Presented by Ed Schafer, M.D., Omaha, Nebraska (USA)